Tag: NCT02362594

Home / NCT02362594

Categories

Pembrolizumab is approved by FDA for adjuvant treatment of melanoma

On February 15, 2019, pembrolizumab (KEYTRUDA, Merck) was approved by the Food and Drug Administration for the adjuvant treatment of patients with melanoma with the involvement of lymph node(s) after ...
nct02362594

Scan the code